You are here

  • Home
  • Archive
  • Volume 27, Issue 3
  • When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

Article metrics

Article menu
Download PDFPDF
EBM opinion and debate
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

 

Online download statistics by month:

Online download statistics by month: June 2021 to May 2023

AbstractFullPdf
Jun 202124212142
Jul 2021582715
Aug 2021301910
Sep 202121132
Oct 202113791
Nov 2021201157
Dec 202129662
Jan 2022185163
Feb 2022274107
Mar 202215381
Apr 2022139112
May 20224552012
Jun 20223122712
Jul 20223362015
Aug 202213995
Sep 202210292
Oct 202211263
Nov 20229252
Dec 20227995
Jan 20239943
Feb 202311462
Mar 202310131
Apr 20236743
May 20234641
Total3790381158